For instance, in the case of sunitinib, a receptor tyrosine kinase inhibitor used as a first-line treatment of RCC, resistance commonly develops within 6 to 15 months of treatment in the majority of patients [5]. This evidence concerns the gene NTRK1 and renal cell carcinoma.